Brief: Zealand Pharma Fy Revenue Up At DKK 9,215 Million
19/02/2026 06:13
Feb 19 (Reuters) - Zealand Pharma A/S ZELA.CO: 2026 OUTLOOK: NET OPERATING EXPENSES, EXCLUDING. OOI DKK 2,700 - 3,300 MILLION FY OPERATING RESULT DKK 6,959 MILLION FY REVENUE DKK 9,215 MILLION Source text: ID:nGNE9G69sX Further company coverage: ZELA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)